Back to News
Market Impact: 0.15
Odyssey Therapeutics Announces Encouraging Phase 2a Ulcerative Colitis Results
Source: Nasdaq
Healthcare & Biotech
Odyssey Therapeutics announced data from the completed induction period of its Phase 2a trial evaluating OD-001 in patients with moderate-to-severe ulcerative colitis. The article excerpt provides no efficacy, safety, or other trial results.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
Ticker Sentiment
ODTX0.10
More News
- A top medical technology stock is trading at a big discount. Here's why I'm buying
- Obsessed with CoreWeave and the AI trade? You're missing out on some great stocks
- UnitedHealthcare and Humana are ending Medicare Advantage plans for nearly 1 million people
- Why is Intuitive Surgical stock sliding today?
- Disc Medicine prices $450 million stock offering at $75/share
- Alpha Teknova stock tumbles on public offering announcement